in

Mycoplasma pneumoniae

# Enzyme immunoassays for the diagnostics of Mycoplasma infection

**ELISA**, **IMUNOBLOT**, and **MICROBLOT-ARRAY** kits are optimized and validated for detection of IgA, IgG, and IgM antibodies in human serum and plasma



Diagnostic kits are intended for professional use in the laboratory.



#### Introduction

*Mycoplasma pneumoniae* is a primary pathogenic agent of the human respiratory tract. It causes pneumonia accompanied by fever, nausea, ague, cough and fatigue. The disease is prolonged but well curable with antibiotics. The pathogen is airborne, spread especially in dense gatherings of children, particularly during spring and autumn months.

#### **Diagnosis of Infection**

Diagnosis of the disease is based on the overall clinical picture, epidemiological anamnesis and laboratory tests. Because it is difficult to cultivate *Mycoplasma pneumoniae*, it is advisable to use the ELISA method for the detection of specific antibodies in human serum or plasma in routine laboratory practice.


### Diagnostic Importance of Antibody Classes

**IgM:** Primary infection is indicated by IgM antibody increase (1-2 weeks after infection), which reaches maximum after 1 month from the beginning of infection. The antibody can persist for more than 1 year. Presence of specific IgM antibody in infected persons under 20 years of age is 80% but only 40% in subjects more than 20 years of age. During reinfection the antibody level rarely rises.

**IgA:** Specific IgA antibody usually increases later than IgM and often decreases earlier. Its significance becomes obvious when IgM antibody is absent in some patients or in case of reinfection.

**IgG:** Specific IgG antibody rises 2–3 weeks after symptoms appearance with maximum reached after longer period (about 6 months) and the antibody can persist for more than 1 year, in some cases even more than 4 years. In case of reinfection it is necessary to evaluate dynamics of antibodies by reinvestigation of paired samples collected in the course of 1 to 2 weeks.

It is advisable to examine each sample for all three antibody classes to evaluate the serological results, eventually to perform reinvestigation of paired samples.




#### **Antibody Responses**

## ELISA



### **Test Principle**

The assays are based on a sandwich type of ELISA method.



### **Summary Protocol**

<u>Step</u>		Test steps
U	1.	Dilute samples - serum/plasma 1:101 (10 μl + 1 ml)
٩	2.	Pipette controls and diluted samples 100 μl - blank = empty well
0	3.	Incubate 30 min. at 37 °C
8	4.	Aspirate and wash the wells 5 times
٩	5.	Add 100 µl Conjugate - blank = empty well
C	6.	Incubate 30 min. at 37 °C
8	7.	Aspirate and wash the wells 5 times
٩	8.	Add 100 µl Substrate (TMB-Complete) - Including blank
•	9.	Incubate 30 min. at 37 °C
٩	10.	Add 100 µl Stopping solution - Including blank
	11.	Read colour intensity at 450 nm

### Antigens

#### **EIA Mycoplasma**

Purified and inactivated *M. pneumoniae* antigen enriched with highly specific immunodominant epitopes

#### **EIA Mycoplasma REC**

Mixture of highly specific recombinant antigens

## **Clinical Application**

- Screening test for the detection of infection with Mycoplasma pneumoniae in humans
- Checking of therapy results using the semiquantitative or quantitative determination.

### **User Comfort**

- Ready-to-use components
- Colour-coded components
- Interchangeable components
- Breakable colour-coded microplate strips
- CUT-OFF and Calibrators included
- Semiquantitative evaluation of results (Index of Positivity)
- Quantitative evaluation of results (U/ml)
- Easy assay procedure

#### **Advantages**

- Identical assay procedure
- High diagnostic specificity and sensitivity
- High reproducibility
- High dynamics of antibody response
- Expiration period of 15 months from date of production
- Short total assay time
- Ready for automation
- Customer support



## **Test Characteristics**

ELISA	Diagnostic Sensitivity	Diagnostic Specificity
EIA Mycoplasma IgA	99.9%	84.6%
EIA Mycoplasma IgG	99.9%	85.7%
EIA Mycoplasma IgM	96.7%	98.8%
EIA Mycoplasma REC IgA	95.0%	95.4%
EIA Mycoplasma REC lgG	95.4%	95.5%
EIA Mycoplasma REC IgM	99.0%	97.7%

## **Types of Kits**

SmartEIA kits are designed for automated processing using the Agility® analyser.

EIA



#### SmartEIA






## IMMUNOBLOT

## **Test Principle**

Recombinant antigens are transferred to a nitrocellulose membrane using a micro-dispensing method.



## Antigens

<b>BLOT-LINE</b>		<b>P1</b> – Adhesin; the most important
Mycoplasma		protein, a major
_		virulence factor
		<b>p30</b> – Cytadhesin p30; the second
		most important
		protein, a major virulence factor
		<b>p116</b> – Adhesin, a major virulence
	Control line IgA	factor
	lgG IgM	<b>p65</b> – Surface protein; proline-rich
	Štart	P65 protein
		HMW3 - Cytadherence high mole-
	P1	cular weigh 3;
H	p30	adhesion-promoting protein
$\square$	p116	Mgp3 – Adhesion-promoting
Н	p65	protein
H	HMW3	
	Mgp3	

## **Summary Protocol**

<u>Step</u>		Test steps
٩	1.	Pipette Universal solution 2.5 ml
0	2.	Strips soaking 10 min. at room temperature - Shaker
8	3.	Aspirate
Ū	4.	Dilute samples - serum/plasma 1:51 (30 µl + 1.5 ml)
٩	5.	Pipette Controls and diluted samples 1.5 ml
C	6.	Incubate 30 min. at room temperature - Shaker
8	7.	Aspirate samples and wash strips with 1.5 ml of Universal solution 3-times for 5 min. - Shaker
٢	8.	Pipette Conjugate 1.5 ml
ľ	9.	Incubate 30 min. at room temperature - Shaker
8	10.	Aspirate Conjugate and wash strips with 1.5 ml of Universal solution 3-times for 5 min. - Shaker
٢	11.	Pipette Substrate solution (BCIP/NBT) 1.5 ml
¢	12.	Incubate 15 min. at room temperature - Shaker
8	13.	Aspirate Substrate solution and wash strips with 2 ml of distilled water 2-times for 5 min. - Shaker
	14.	Sticking and evaluation of strips

### **Clinical Application**

- Detailed determination for the presence of anti-Mycoplasma specific antibodies
- Confirmation of ambiguous results
- Confirmation for ELISA tests

### **User Comfort**

- Ready-to-use components
- Colour-coded strips
- Interchangeable components
- Positive and Negative controls
- Control line is present on the strip
- Possibility of software evaluation

#### **Advantages**

- Identical assay procedure
- Easy interpretation and reproducibility of results
- Sophisticated evaluation software
- High diagnostic efficiency
- Ready for automation
- Customer support

### **Test Characteristics**

Pathogen	<u>Diagnostic</u> Sensitivity	<u>Diagnostic</u> Specificity
BLOT-LINE Mycoplasma IgA	93.3%	93.7%
BLOT-LINE Mycoplasma IgG	92.4%	96.0%
BLOT-LINE Mycoplasma IgM	90.3%	95.1%

#### IMMUNOBLOT




## Interpretation Results

lgG	<u>IgA</u>	<u>IgM</u>	Interpretation
-	-	-	No serological evidence of Mycoplasma pneumoniae infection
-	+	+	Early phase of acute infection or reinfection
-	+	-	Early phase of acute infection or reinfection
+	+	+	Acute infection
+	-	+	Acute infection (late phase)
+	+	-	Reinfection or infection without IgM production
+	-	-	Past infection or reinfection
-	-	+	Early phase of acute infection



## MICROBLOT-ARRAY

## Distribution of Antigens and Control Spots



#### **Description of antigens**

- **A1** P1
- **A2** P30
- **A3** P116
- **A4** P65
- **A5** HMW3
- **A6** Mgp3

#### **Description of control spots**

R	_	Reference

- **TC** Test control
- CA Conjugate control IgA
- CG Conjugate control IgG
- **C1** Calibration 1
- **C2** Calibration 2
- **C3** Calibration 3
- **C4** Calibration 4

### **Protocol Summary**

<u>Step</u>		Test steps
٢	1.	Pipette Universal solution 150 µl
•	2.	Strips soaking 10 min. at room temperature
8	3.	Aspirate
U	4.	Dilute samples - serum/plasma 1:51 (10 µl + 500 µl)
٢	5.	Pipette Controls and diluted samples 100 µl
C	6.	Incubate 30 min. at room temperature
8	7.	Aspirate samples and wash strips with 150 µl of Universal solution 3-times for 5 min.
٩	8.	Pipette Conjugate 100 µl
C	9.	Incubate 30 min. at room temperature
8	10.	Aspirate samples and wash strips with 150 µl of Universal solution 3-times for 5 min.
٩	11.	Pipette Substrate solution (BCIP/NBT) 100 µl
0	12.	Incubate 15 min. at room temperature
8	13.	Aspirate Substrate solution and wash strips with 200 µl of distilled water 2-times for 5 min.
	14.	Dry and evaluate strips

#### INFECTIOUS SEROLOGY - BACTERIOLOGY - MYCOPLASMA PNEUMONIAE



### **User Comfort**

- Low sample consumption
- Antigens spotted in triplicate minimizing statistical variation
- Possibility of automatic processing and results evaluation
- Parallel testing of multiple markers simultaneously
- High sensitivity and specificity

#### Microblot-Array



## **Test Characteristics**

Pathogen	Diagnostic Sensitivity	<b>Diagnostic Specificity</b>
Microblot-Array Mycoplasma IgA	97.1%	99.3%
Microblot-Array Mycoplasma IgG	95.7%	99.0%





## **Cross-reactivity**

#### of the kit Mycoplasma IgA on a panel of potentially cross-reactive samples

<u>n</u>	<u>Positive</u> <u>Result</u>	<u>Negative</u> <u>Result</u>	Cross-reactivity
22	1	21	4.6%
21	0	21	0.0%
22	1	21	4.6%
23	1	22	4.4%
16	0	16	0.0%
15	0	15	0.0%
3	0	3	0.0%
	22 21 22 23 16 15	Result   22 1   21 0   22 1   23 1   16 0   15 0	n Result Result   22 1 21   21 0 21   22 1 21   22 1 21   23 1 22   16 0 16   15 0 15

#### of the kit Mycoplasma IgG on a panel of potentially cross-reactive samples

Category	<u>n</u>	<u>Positive</u> <u>Result</u>	Negative Result	Cross-reactivity
RF	22	1	21	0.0%
EBV	21	0	21	0.0%
ANA	22	1	21	0.0%
Chlamydia pneumoniae	23	1	22	0.0%
Bordetella pertussis	16	0	16	0.0%
CMV	15	0	15	0.0%
Legionella pneumophila	3	0	3	0.0%

Potential cross-reactivity with other related pathogens and factors is insignificant (less than 5%).



## **Ordering Information**

#### ELISA

Cat. No.	Product	No. of Wells
MyA096	EIA Mycoplasma IgA	96
MyG096	EIA Mycoplasma IgG	96
MyM096	EIA Mycoplasma IgM	96
MyAR96	EIA Mycoplasma REC IgA	96
MyGR96	EIA Mycoplasma REC IgG	96
MyMR96	EIA Mycoplasma REC IgM	96
SK-MyA096	SmartEIA Mycoplasma IgA	96
SK-MyG096	SmartEIA Mycoplasma IgG	96
SK-MyM096	SmartEIA Mycoplasma IgM	96
SK-MyAR96	SmartEIA Mycoplasma REC IgA	96
SK-SK-MyGR96	SmartEIA Mycoplasma REC IgG	96
SK-MyMR96	SmartEIA Mycoplasma REC IgM	96

.

SmartEIA kits are designed for automated processing using the Agility® analyser

#### IMMUNOBLOT

Cat. No.	Product	<u>No. of Tests</u>
MyAL20	BLOT-LINE Mycoplasma IgA	20
MyGL20	BLOT-LINE Mycoplasma IgG	20
MyML20	BLOT-LINE Mycoplasma IgM	20
SwIm03	Immunoblot Software	1





## **Ordering Information**

#### MICROBLOT-ARRAY

Cat. No.	Product	<u>No. of Tests</u>
MyAMA48	Microblot-Array Mycoplasma IgA	48
MyGMA48	Microblot-Array Mycoplasma IgG	48









#### TestLine Clinical Diagnostics Ltd.

Krizikova 68, 612 00 Brno, Czech Republic +420 549 121 203 sales@testlinecd.com www.testlinecd.com



Company is certified to the quality management system standards ISO 9001 and ISO 13485 for in vitro diagnostics.

in